The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor–Null Mice With Diet-Induced Insulin Resistance
Open accessAbstract
OBJECTIVE: The global epidemic of metabolic syndrome and its complications demands rapid evaluation of new and accessible interventions. Insulin resistance is the central biochemical disturbance in the metabolic syndrome. The citrus-derived flavonoid, naringenin, has lipid-lowering properties and inhibits VLDL secretion from cultured hepatocytes in a manner resembling insulin. We evaluated whether naringenin regulates lipoprotein production and insulin sensitivity in the context of insulin resistance in vivo. RESEARCH DESIGN AND METHODS: LDL receptor–null (Ldlr−/−) mice fed a high-fat (Western) diet (42% calories from fat and 0.05% cholesterol) become dyslipidemic, insulin and glucose intolerant, and obese. Four groups of mice (standard diet, Western, and Western plus 1% or 3% wt/wt naringenin) were fed ad libitum for 4 weeks. VLDL production and parameters of insulin and glucose tolerance were determined. RESULTS: We report that naringenin treatment of Ldlr−/− mice fed a Western diet corrected VLDL overproduction, ameliorated hepatic steatosis, and attenuated dyslipidemia without affecting caloric intake or fat absorption. Naringenin 1) increased hepatic fatty acid oxidation through a peroxisome proliferator–activated receptor (PPAR) γ coactivator 1α/PPARα-mediated transcription program; 2) prevented sterol regulatory element–binding protein 1c–mediated lipogenesis in both liver and muscle by reducing fasting hyperinsulinemia; 3) decreased hepatic cholesterol and cholesterol ester synthesis; 4) reduced both VLDL-derived and endogenously synthesized fatty acids, preventing muscle triglyceride accumulation; and 5) improved overall insulin sensitivity and glucose tolerance. CONCLUSIONS: Thus, naringenin, through its correction of many of the metabolic disturbances linked to insulin resistance, represents a promising therapeutic approach for metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 2×
“Peroxisome prolifertor–activated receptor (PPAR) coactivator 1 (PGC1 ) activation can initiate mitochondrial biogenesis (28).”
BackgroundInsulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Boden, G., & Shulman, G. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.3.x · Cited by 1,300
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Selective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965
Cited by
Alam, M. A., Subhan, N., Rahman, M. M., Uddin, S. J., Reza, H. M., & Sarker, S. D. (2014) · Advances in Nutrition · doi:10.3945/an.113.005603 · Cited by 788
AL-Ishaq, R. K., Abotaleb, M., Kubatka, P., Kajo, K., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9090430 · Cited by 741
Antidiabetic Properties of Dietary Flavonoids: A Cellular Mechanism Review
Vinayagam, R., & Xu, B. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0057-7 · Cited by 597
He, B., Nohara, K., Park, N., Park, Y.-S., Guillory, B., Zhao, Z., Garcia, J. M., Koike, N., Lee, C. C., Takahashi, J. S., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.007 · Cited by 507
Beneficial effects of naringenin in liver diseases: Molecular mechanisms
Hernández-Aquino, E., & Muriel, P. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i16.1679 · Cited by 347
Wang, Q., Ou, Y., Hu, G., Wen, C., Yue, S., Chen, C., Xu, L., Xie, J., Dai, H., Xiao, H., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14938 · Cited by 309
Naringenin as a potential immunomodulator in therapeutics
Zeng, W., Jin, L., Zhang, F., Zhang, C., & Liang, W. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.002 · Cited by 305
Mozaffarian, D., & Wu, J. H. Y. (2018) · Circulation Research · doi:10.1161/circresaha.117.309008 · Cited by 303
Antidiabetic Properties of Naringenin: A Citrus Fruit Polyphenol
Den Hartogh, D. J., & Tsiani, E. (2019) · Biomolecules · doi:10.3390/biom9030099 · Cited by 267
Salomone, F., Godos, J., & Zelber‐Sagi, S. (2016) · Liver International · doi:10.1111/liv.12975 · Cited by 260
Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies
Mollace, V., Sacco, I., Janda, E., Malara, C., Ventrice, D., Colica, C., Visalli, V., Muscoli, S., Ragusa, S., Muscoli, C., et al. (2011) · Fitoterapia · doi:10.1016/j.fitote.2010.10.014 · Cited by 246
Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
Mulvihill, E. E., Burke, A. C., & Huff, M. W. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-050718 · Cited by 228
Self-citationFlavonoids as Antiobesity Agents: A Review
Rufino, A. T., Costa, V. M., Carvalho, F., & Fernandes, E. (2021) · Medicinal Research Reviews · doi:10.1002/med.21740 · Cited by 174
Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
Chattopadhyay, D., Sen, S., Chatterjee, R., Roy, D., James, J., & Thirumurugan, K. (2016) · Biogerontology · doi:10.1007/s10522-015-9624-6 · Cited by 21
Metadata
- Authors
- Mulvihill, E. E., Allister, E. M., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Markle, J. M., Hegele, R. A., & Huff, M. W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-07-10
- Volume
- 58
- Issue
- 10
- Pages
- 2198-2210
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2149098343
- Cited by
- 297
- References
- 52
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.